{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:50:34Z","timestamp":1793893834349,"version":"4.8.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"\n Importance<\/jats:title>\n Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin\/doxorubicin, oncovin, and prednisone\/prednisolone (CHOP)\u2013based regimens.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter, intergroup study was conducted at academic and community practice locations throughout the US and enrolled patients with untreated, advanced-stage FL. Cure modeling, which involves estimating the proportion of patients cured of the disease, was conducted by incorporating background mortality rates to estimate the proportion of patients cured of FL during the S0016 trial. Patients were enrolled between May 2001 and October 2008 and followed up for a median (IQR) of 15.5 (13.6-16.9) years. The 15-year analysis was conducted in June 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized to receive either rituximab plus CHOP (R-CHOP) or CHOP followed by radioimmunotherapy (CHOP-RIT).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes<\/jats:title>\n The main outcomes were 15-year progression free survival (PFS) and overall survival (OS). Secondary outcomes included cure modeling.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 531 eligible patients (242 female patients [46%]; median [IQR] age, 53 [45-61] years) were included in the final analysis (267 [50%] received R-CHOP and 264 [50%] CHOP-RIT). The overall 15-year OS was 70%, with no significant difference between treatment arms, and the 15-year PFS was 40% (95% CI, 36.0%-44.7%). CHOP-RIT demonstrated superior 15-year PFS (47% vs 34%;\n P<\/jats:italic>\n \u2009=\u2009.004) compared with R-CHOP. Cure modeling estimated an overall cure rate of 42%, with the highest cure rates observed in patients with low Follicular Lymphoma International Prognostic Index scores and normal \u03b22 microglobulin levels. The rate of relapse declined substantially over time, from 6.8% during the first 5 years to 0.6% between 15 to 20 years.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this secondary analysis suggest that a subset of patients with advanced-stage FL can achieve cure with CHOP-based chemoimmunotherapy, as relapse rates decline over time. This finding represents a paradigm shift in the understanding of and approach to FL, with implications for initial patient discussions and future research strategies.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT00006721<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.0042","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:30:35Z","timestamp":1772123435000},"page":"394","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy"],"prefix":"10.1001","volume":"12","author":[{"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[{"name":"Fred Hutch Cancer Center, Seattle, Washington"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, Seattle, Washington"},{"name":"SWOG Statistical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rimsza","sequence":"additional","affiliation":[{"name":"University of Arizona, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, Seattle, Washington"},{"name":"SWOG Statistical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"23","key":"coi260002r1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas.","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"33","key":"coi260002r2","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma.","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi260002r3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma.","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"coi260002r4","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study.","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"key":"coi260002r5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hon.3138","article-title":"Update on follicular lymphoma.","volume":"41","author":"Friedberg","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1","key":"coi260002r6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2012.41.7527","article-title":"Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?","volume":"31","author":"Cabanillas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi260002r7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"7","key":"coi260002r8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016.","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi260002r9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi260002r10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"25","key":"coi260002r11","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911.","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"issue":"466","key":"coi260002r12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"coi260002r13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"14","key":"coi260002r14","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-11-2859","article-title":"Cure models as a useful statistical tool for analyzing survival.","volume":"18","author":"Othus","year":"2012","journal-title":"Clin Cancer Res"},{"key":"coi260002r15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01918","article-title":"Using cure models for trial analysis and design.","volume":"JCO2401918","author":"LeBlanc","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi260002r18","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine\u2013tositumomab.","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10","key":"coi260002r19","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi260002r20","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi260002r21","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study.","volume":"7","author":"Townsend","year":"2023","journal-title":"Hemasphere"},{"issue":"15","key":"coi260002r22","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study.","volume":"35","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi260002r23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.19213","article-title":"R-CHOP treatment for patients with advanced follicular lymphoma: over 15-year follow-up of JCOG0203.","volume":"204","author":"Watanabe","year":"2024","journal-title":"Br J Haematol"},{"issue":"28","key":"coi260002r24","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma.","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi260002r25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.clml.2023.07.012","article-title":"Very late relapse in Hodgkin lymphoma: characterizing an understudied population.","volume":"23","author":"Cherniawsky","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"coi260002r26","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1200\/JCO.19.00014","article-title":"Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"37","author":"Wang","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi260002r27","doi-asserted-by":"publisher","DOI":"10.1002\/pon.70103","article-title":"Unmet needs and health-related quality of life among patients with relapsed\/refractory indolent non-Hodgkin lymphoma: a mixed-methods study.","volume":"34","author":"Sugimoto","year":"2025","journal-title":"Psychooncology"},{"issue":"7","key":"coi260002r28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7095","article-title":"Patterns of follow-up care in adult blood cancer survivors\u2014prospective evaluation of health-related outcomes, resource use, and quality of life.","volume":"13","author":"Lax","year":"2024","journal-title":"Cancer Med"},{"issue":"8","key":"coi260002r29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"17","key":"coi260002r30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update.","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"5","key":"coi260002r31","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"coi260002r32","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"33","key":"coi260002r33","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma.","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi260002r34","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.clml.2024.04.009","article-title":"Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease.","volume":"24","author":"Chauhan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"coi260002r35","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1182\/blood-2023-179612","article-title":"Minimal residual disease (MRD) status predicts outcomes in patients with follicular lymphoma (FL) treated with chemo-immunotherapy on SWOG S0016.","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"issue":"5","key":"coi260002r36","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/S2352-3026(25)00034-1","article-title":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.","volume":"12","author":"Northend","year":"2025","journal-title":"Lancet Haematol"},{"key":"coi260002r37","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00037","article-title":"SWOG 2308: randomized phase III study of mosunetuzumab versus rituximab for low-tumor burden follicular lymphoma.","volume":"2","author":"Ghosh","year":"2025","journal-title":"JCO Oncology Advances"},{"issue":"1","key":"coi260002r38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"},{"issue":"24","key":"coi260002r39","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1182\/blood.2024024496","article-title":"Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance.","volume":"144","author":"Laurent","year":"2024","journal-title":"Blood"},{"issue":"4","key":"coi260002r40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.semnuclmed.2024.06.002","article-title":"The rebirth of radioimmunotherapy of non-Hodgkin lymphoma: the phoenix of nuclear medicine?","volume":"54","author":"Wahl","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"6","key":"coi260002r41","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5).","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"8","key":"coi260002r42","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"coi260002r43","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after =2 prior therapies.","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"coi260002r44","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1182\/blood-2024-197897","article-title":"Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and\/or refractory follicular lymphoma after =2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study.","volume":"144","author":"Shadman","year":"2024","journal-title":"Blood"},{"issue":"11","key":"coi260002r45","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"coi260002r46","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"coi260002r16","unstructured":"Jackson? C. Flexible parametric cure models. Accessed August 1, 2025. https:\/\/cran.r-project.org\/package=flexsurvcure"},{"key":"coi260002r17","unstructured":"University of California. United States Mortality DataBase. Accessed July 1, 2024. https:\/\/usa.mortality.org\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2845507\/jamaoncology_shadman_2026_oi_260002_1775759212.4375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:31Z","timestamp":1776351631000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2845507"}},"subtitle":["15-Year Follow-Up of the SWOG S0016 Trial"],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.0042","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}